Photomicrograph of a Nerium oleander leaf.
Nerium oleander cultivation.
Photomicrograph of human nerve cells.

Phoenix Biotechnology, Inc. (PBI)'s Focus

Phoenix Biotechnology, Inc., has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.

PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.

A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.

News

September, 2020
The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties". Colapietro Alessandro, Yang Peiying, Rossetti Alessandra, Mancini Andrea, Vitale Flora, Martellucci Stefano, Conway Tara L., Chakraborty Sharmistha, Marampon Francesco, Mattei Vincenzo, Gravina Giovanni Luca, Biordi Assunta Leda, Wei Daoyan, Newman Robert A., Festuccia Claudio. Frontiers in Pharmacology.

READ RESEARCH ARTICLE

July, 2020
Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin” – was produced following research conducted this spring and summer by scientists at the University of Texas Medical Branch in Galveston, Texas, the University of Texas MD Anderson Cancer Center and Phoenix Biotechnology, Inc. Any product(s) resulting from this research will not be available until approved by the US Food & Drug Administration.

READ THE PREPRINT